Notably, the nanocarrier system targeting FABP5 elevates PD‐L1 expression, and the combination of RFA with anti‐PD‐L1 therapy demonstrates synergistic efficacy against HCC. The gene discussed is FABP5; the disease is hepatocellular carcinoma.